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[57] ABSTRACT 
An apparatus for analyzing the chemical composition of 
tissue includes a near infrared light source, a ?ber-optic 
probe, a mechanism for directing the light from the 
light source onto the tissue and detectors for detecting 
light re?ected by the tissue. The light source transmits 
an incident beam having a wavelength ranging from 
1000 to 2500 nm. A compound parabolic concentrator 
(CPC) is connected to a distal end of the ?ber optic 
probe to focus or concentrate the wavelengths of light 
simultaneously and in parallel on a particular spot of 
tissue. Alternatively, an inverted, substantially conical 
re?ector is positioned to scatter the incident light across 
the tissue. The method includes the steps of (1) focusing 
light onto the tissue to be analyzed; (2) detecting light 
re?ected by the tissue; and (3) analyzing the resulting 
spectra across the full wavelength of the originally 
focused light. A color image is then produced for subse 
quent study. 
8 Claims, 5 Drawing Sheets 
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APPARATUS AND METHOD FOR MULTIPLE 
WAVELENGTH OF TISSUE 
This invention was made with government support 
under NSF RII-86l0671 and NIH BRSG S07 RR05857 
09 awarded by The National Science Foundation and 
National Institute of Health, respectively. The govern 
ment has certain rights in the invention. 
This application is a continuation-in-part of US. pa 
tent application Ser. No. 07/695,104, ?led May 3, 1991 
now abandoned. 
‘TECHNICAL FIELD 
The present invention relates generally to medical 
research and diagnostics and, more particularly, to a 
method and apparatus adapted to produce spectra that 
are indicative of the chemical composition of tissue and 
in a more particular application, the inner walls of arter 
ies in vivo. 
BACKGROUND OF THE INVENTION 
A number of techniques have been utilized in the past 
to make constituent identi?cations in atherosclerotic 
lesions. These techniques include HPLC, NMR chemi 
cal-shift imaging and immunocytochemistry. Atheroma 
recognition has been performed by other techniques 
including duplex ultrasound and pneumoplethysmogra 
phy. Atheroma classi?cation has been made by micro 
scopic and histologic examinations. Additionally, spa 
tial pro?ling has been accomplished by chemical analy 
sis, enzymatic assays and immuno?uorescence tech 
niques. 
While all of these different techniques and technolo 
gies are useful in qualitatively analyzing atherosclerotic 
lesions and plaques in vitro, it should be appreciated 
that new technologies used for treating atherosclerotic 
lesions and plaques require a reliable method of in vivo 
lesion and plaque recognition to be most effective. A 
need therefore exists for a reliable apparatus and 
method for the chemical examination of arterial endo 
thelium and, more particularly, for analyzing the com 
position of atherosclerotic lesions and plaques in living 
tissue. 
SUMMARY 0F THE INVENTION 
Accordingly, it is a primary object of the present 
invention to provide a method and apparatus for analyz 
ing tissue and particularly arterial tissue and the lesions 
and plaques associated therewith in a manner overcom 
ing the above-described limitations and disadvantages 
of the prior art. 
1 Another object of the present invention is to provide 
an apparatus and method that may not only be used in in 
vitro analysis but is also adapted for in vivo analysis. 
Advantageously, such an apparatus and method may be 
utilized to not only localize lesions but to evaluate the 
progression of disease and the effectiveness of treat 
ment. More particularly, by permitting the actual 
growth of lesions as well as the effectiveness of treat 
ment to be studied as it is being administered, improved 
treatment programs may be designed. 
Yet another object of the present invention is to pro 
vide a method and apparatus speci?cally adapted to 
identify different lesion types to thereby allow physi 
cians to prescribe appropriate drugs that are more likely 
to provide effective treatment. This is a particularly 
important consideration when it is realized that some of 
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the drugs prescribed to treat lesions have serious side 
effects. 
Still another object is to provide a method and appa 
ratus wherein infrared radiation of a wavelength range 
spanning substantially 1000-2500 nm and, more prefera 
bly, 1500-2100 nm is simultaneously focused onto the 
arterial endothelium under study. The re?ected infrared 
radiation is then detected and analyzed at high speed to 
not only identify lesions but also evaluate the progres 
sion of disease and effectiveness of treatment. 
Additional objects, advantages and other novel fea 
tures of the invention will be set forth in part in the 
description that follows and in part will become appar 
ent to those skilled in the art upon examination of the 
following or may be learned with the practice of the 
invention. The objects and advantages of the invention 
may be realized and obtained by means of the instru 
mentalities and combinations particularly pointed out in 
the appended claims. 
To achieve the foregoing and other objects, and in 
accordance with the purposes of the present invention 
as described herein, an improved apparatus is provided 
for analyzing tissue including arterial lesions. The appa 
ratus may not only be utilized for in vitro analysis but 
also, advantageously may be utilized for in vivo analy 
sis. The apparatus comprises alight source for transmit 
ting simultaneously and in parallel an incident beam of 
light of a wavelength range from 1000 to 2500 nm and 
more preferably from 1500 to 2100 nm. A ?ber optic 
probe is operatively connected to the light source. A 
light directing or focusing mechanism is mounted to the 
distal end of the probe. The focusing mechanism may 
comprise a compound parabolic concentrator (CPC) 
that may, for example, be formed from plastic and in 
clude a polished aluminum lining. The CPC is similar to 
those designed for use for solar power concentration. 
The CPC is adapted to compress the incident beam 
from the transmitting ?ber optic onto a small spot on 
the tissue surface undergoing analysis. Additionally, the 
apparatus includes detectors, such as lead sul?de detec 
tors, for detecting the scattered light from the artery 
surface or other tissue being analyzed. 
In an alternative embodiment, the light directing 
mechanism comprises an inverted, substantially conical 
re?ector developed from both ellipsoids of rotation and 
paraboloids of rotation. This re?ector serves to direct 
the incident beam from the transmitting optic ?ber over 
the tissue undergoing analysis. Additionally, light re 
?ected by the tissue is directed or focused into receiving 
optic ?bers so as to allow for better detection and 
hence, chemical analysis of the tissue. 
The apparatus further includes means for high speed 
parallel analyzing of the spectra re?ected from the tis 
sue and producing color images thereof. Such a means 
may, for example, comprise a supercomputer, such as 
available at the University of Kentucky, and appropri 
ate software such as the copyrighted Best Algorithm 
software program developed by co-inventor, Robert A. 
Lodder. Further, the ?ber optic probe of the apparatus 
is preferably adapted for introduction into a patient to 
thereby allow in vivo analysis of tissue and particularly 
the walls of arteries. This means may comprise any 
catheter assembly appropriate for this purpose. 
In accordance with a further aspect of the present 
invention, a method of analyzing tissue including arte 
rial lesions is provided. The method broadly includes 
the steps of focusing light on the tissue to be analyzed 
and detecting light re?ected by the tissue. As indicated 
5,441,053 
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above, the light being focused is of a wavelength range 
from 1000 to 2500 and more preferably 1500 to 2100 nm. 
The method further includes a step of analyzing the 
spectra from the tissue and producing color images 
thereof. Advantageously, both the focusing and analyz 
ing steps are performed to allow high speed data acqui 
sition and analysis. Speci?cally light having a range of 
wavelengths from 1000 to 2500 nm and more preferably 
1500 to 2100 nm is simultaneously focused in parallel at 
all locations being analyzed. The analysis of the re 
?ected light is also completed simultaneously and in 
parallel for all locations being analyzed over the same 
range of wavelengths. As all tissues absorb light at all 
these wavelengths, with different tissues absorbing only 
a little more at some wavelengths than others, this 
broad band parallel approach is necessary to insure that 
no unusual tissue is missed during study. Hence, the 
analysis is more accurate and complete. Further, as the 
focusing and analysis are performed in parallel the com 
plete study may still be completed in a suf?ciently short 
time span to allow clinical utilization such as for arterial 
angiography. In accordance with a further method of 
analyzing arterial endothelium in vivo utilizing a ?ber 
optic probe, the method includes the initial step of intro- ' 
ducing the probe into an artery of a patient. 
Still other objects of the present invention will be 
come apparent to those skilled in this art from the fol 
lowing description wherein there is shown and de 
scribed a preferred embodiment of this invention, sim 
ply by way of illustration of one of the modes best 
suited to carry out the invention. As it will be realized, 
the invention is capable of other different embodiments 
and its several details are capable of modi?cation in 
various, obvious aspects all without departing from the 
invention. Accordingly, the drawings and descriptions 
will be regarded as illustrative in nature and not as 
restrictive. 
BRIEF DESCRIPTION OF THE DRAWING 
The accompanying drawing incorporated in and 
forming a part of this speci?cation illustrates several 
aspects of the present invention and together with this 
description serves to explain the principles of the inven 
tion. In the drawing: 
FIG. 1 is a schematical representation of one embodi 
ment of the apparatus of the present invention including 
a compound parabolic concentrator for the analysis of 
tissue; 
FIG. 2 is a schematical representation of a second, 
alternative embodiment of the present invention includ 
ing an inverted, substantially cone-shaped re?ector; 
FIG. 3 is a distal end view of the ?ber optic bundle 
used in the apparatus of the present invention; 
FIG. 4 is a black and white representation of a color 
photographic image showing the lipoprotein composi 
tion of a thoracic aorta incubated in Kreb’s physiolog 
ical salt solution; 
FIG. 5 is another black and white representation of a 
color photographic image showing the lipoprotein 
composition of a thoracic aorta incubated in Kreb’s 
physiological salt solution that also contained low-den 
sity lipoprotein; 
FIG. 6 is a graphical representation depicting the 
spectral vector of the principal axis transformation ma 
trix corresponding to the spectral change observed in 
the aorta specimens incubated in low-density lipopro 
tem; 
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FIG. 7 is a graphical representation summarizing the 
process by which colors were assigned to pixels in the 
black and white representations of the color images of 
FIGS. 4 and 5; and 
FIGS. Sa-c are NIR spectra of human apolipo 
proteins apoA-I, apoA-II and apoB, respectively ob 
tained utilizing the apparatus of the present invention. 
Reference will now be made in detail to the present 
preferred embodiment of the invention an example of 
which is illustrated in the accompanying drawing. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Reference is now made to the drawing ?gures show 
ing the apparatus of the present invention for producing 
and detecting spectra indicative of the chemical compo 
sition of tissue undergoing analysis. Two different em 
bodiments of the present invention are shown and de 
scribed below and in the drawing ?gures. The ?rst 
embodiment shown in FIG. 1 is described below for use 
in analyzing tissue in vitro. The second embodiment 
shown in FIG. 2 is described below for use in analyzing 
tissue and, more particularly, arterial endothelium, in 
vivo. It should be appreciated, however, that the fol 
lowing detailed descriptions are being presented for 
purposes of illustration and explanation, and accord 
ingly, the embodiments are not to be considered as 
being limited to the particular applications being de 
scribed. 
FIG. 1 schematically shows one embodiment of the 
apparatus 10 of the present invention. More particu 
larly, the apparatus 10 includes a ?ber optic probe, 
generally designated by reference numeral 12. The 
probe 12 includes an integrating sphere 14 of a type 
known in the art and formed of any appropriate mate 
rial. A compound parabolic concentrator (CPC) 18 is 
mounted to the integrating sphere 14. The CPC 18 
includes a main body member 20 formed from plastic 
and a polished aluminum lining 22. As is known, the 
CPC 18 also includes a central optical aperture 23 
through which light is directed and focused. This aper 
ture preferably has a diameter between 0.64 and 0.84 
mm2 and more preferably of substantially 0.74 mmz. 
A ?ber optic bundle 24 is rigidly mounted to and held 
in an inlet port 26 in the integrating sphere 14, opposite 
the CPC 18. The ?ber optic bundle 24 (transmitting 
?ber optic) is operatively connected to a light source 30 
(see FIG. 1). The light source 30 is particularly adapted 
for generating a spectrum of light having a wavelength 
range from 1000 to 2500 nm and, more preferably from 
1500 to 2100 nm. Such a light source 30 may, for exam 
ple, be a tungsten-halogen lamp with wavelength selec 
tion being accomplished utilizing a concave holo 
graphic diffraction grating. 
An individual light detector 34 is mounted on the 
wall of the integrating sphere 14. Any appropriate de 
tector known in the-art may be utilized including a lead 
sul?de detector and/or an indium antimonide detector 
cooled with liquid nitrogen. 
Light of from 1000 to 2500 nm and more preferably 
of from 1500 to 2100 nm from the source 30 is directed 
simultaneously and in parallel along the transmitting 
?ber optic bundle 24 to the ?ber optic probe 12. There 
the light from the source 30 is projected as an incident 
beam through the integrating sphere 14, the CPC 18 and 
the aperture 23 onto a tissue sample T (note incident 
light beam depicted in full line by action arrows A). As 
shown even scattered light of the incident beam is redi 
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rected and is concentrated by the CPC 18 so as to be 
tightly focused on a point P of the tissue sample T. 
A signi?cant portion of the incident light projected 
onto the point P of the tissue sample T is re?ected back 
into the CPC 18 through the aperture 23. The scattered, 
re?ected light is shown in dash line with reference to 
action arrow B. As shown, the re?ected light is directed 
by the parabolic walls of the CPC 18 into the integrat 
ing sphere 14. The integrating sphere 14 then directs the 
re?ected light so that it falls upon the detector 34. 
As shown the detector 34 is connected to a means 36 
for analyzing the detected spectra and producing color 
images thereof.‘ Speci?cally, the analysis is completed 
over the full wavelength range of the incident light 
directed upon the tissue. Thus, re?ected light having a 
wavelength range between 1000 to 2500 nm and more 
preferably 1500 to 2100 nm is analyzed simultaneously 
and in parallel. Further, equal weighting is given to 
each wavelength in the analysis, unlike other methods. 
Hence, it should be appreciated that the present method 
is not equivalent to Fourier Transformation (FFT) or 
other data congression techniques like principal compo 
nents (PCA). 
To achieve this end a supercomputer may be utilized 
under the direction of appropriate analytical software 
such as the Best Algorithm software program devel 
oped at the University of Kentucky by Robert A. Lod 
der, a co-inventor of the present invention. The Best 
Algorithm software program calculates the distance of 
the spectrum of each point on the artery wall to the 
center of the distribution of an ordinary arterial wall. 
The user arbitrarily selects colors to denote directions 
of spectra in hyperspace, and hence the identity of 
chemical constituents. Thus, the direction is. color 
coded to identify particular chemical species. Addition 
ally, the length of the vectors (in standard deviations) is 
proportional to the concentration of the chemical spe 
cies in the artery wall at the position where the spectra 
were recorded. 
Thus, the color images are actually color density 
contour plots whose contours represent the mathemati 
cally determined probability of the tissue having a cer 
tain composition. The contours are drawn at set dis 
tances in standard deviations (SDs) from the spectra of 
a normal artery. As you go more and more SDs from 
normal, the probability of being normal (no excess 
LDL) is less. The relationship between SDs and proba 
bility can be looked up in a standard table of the Gauss 
ian distribution. 
All prior art SDs, such as Mahalanobis SDs, are based 
on the assumption that spectral clusters are normally 
distributed and have radial symmetry (either spheroid 
or ellipsoid). In contrast, the SDs of the Best Algorithm 
are asymmetrical. In other words, the length of an SD 
is different in one direction than in the opposite direc 
tion. Accordingly, the SDs of the Best Algorithm are 
better suited to handle asymmetrical spectral distribu 
tions in hyperspace such as produced in complex mix 
tures like atheromas. 
EXAMPLE 1 
False-color “maps” as shown in FIGS. 4 and 5 were 
prepared as described below. The FIGS. 4 and 5 show 
the lipoprotein composition of thoracic aortas obtained 
from two laboratory rats. The aortas were each excised 
and partially denuded. This was done by removing the 
endothelium from a portion of the vessel wall of each 
rate. The aorta specimen shown in FIG. 4 was incu 
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bated for two hours in Kreb’s physiological salt solu 
tion. The aorta specimen shown in FIG. 5 was incu 
bated for two hours in a Kreb’s physiological salt solu 
tion that also contained low density lipoprotein 
(LDL)(500 ug/mL). 
The aortas were washed following incubation and 
passed beneath the CPC 18 of the probe 12 while the 
concentrator was held ?xed. A micropositioning stage 
was used to allow spectra to be collected along the axis 
of the aorta when the aorta was opened to expose the 
internal surface. Both specimens were scanned along a 
track approximately 0.5 X6 mm in dimension. 
FIG. 6 depicts the spectral vector in the principal axis 
transformation matrix. This corresponds to the spectral 
change observed in the artery when the aorta specimen 
was incubated in LDL. The major spectral changes 
were observed near 1560 nm and between 1700 and 
1870 nm. 
FIG. 7 summarizes the process by which the colors 
were assigned to pixels in the images. The “O”s repre 
sent sample spectral obtained from the aorta incubated 
without LDL, and the “+”s represent sample spectra 
obtained from the aorta incubated in the LDL. The 
distances are measured in standard deviations (SDs) in 
spectral hyperspace between the center of aorta spec 
tral points incubated without LDL and each test speci 
men spectral point (the latter point may or may not 
come from an aorta specimen incubated in LDL). 
A parallel assimilation algorithm, R. A. Lodder, and 
G. M. Hiefije, Appl. Spectrosc, 42, 1351-1365 (1988), 
was implemented on an IBM 3090-6001 supercomputer 
to calculate the distances and assemble the results into 
the ?nal color images shown as black and white repre 
sentations. The center of the aorta spectral points incu 
bated without LDL are coded dark blue (DB). Vertical 
motions along the solid lines in FIG. 6 (representing 
base-line shifts that likely correlate to vessel wall thick 
ness) are coded green (G). Horizontal motions along the 
dotted lines shown in FIG. 7 (representing LDL up 
take) are coded pink (P) and red (R). Red represents a 
larger movement in SDs than pink. The contour lines in 
the aortal images are drawn every 0.1 SD, and a color 
change occurs approximately every 3 SDs. 
The image shown in FIG. 4 is predominantly blue (B) 
and green (G). This indicates that the aorta specimen is 
similar to spectra obtained from such tissues incubated 
without LDL. The green (G) portion is caused by a 
base-line shift which likely results from a thickening of 
the aorta wall which brings the specimen closer to the 
optical aperture 23. 
The image shown in FIG. 5 shows nearby orthogonal 
changes that correspond to the uptake of LDL by the 
aorta wall with the red (R) color representing regions of 
maximum uptake of LDL. The LDL enters cells intact 
through receptor-mediated endocytosis (Goodman and 
Gilman, “The Pharmacological Basis of Therapeutics” 
8th ed., Pergamon Press, 1990) and remains intact until 
catabolism of LDL in cellular lysosomes. The choles 
teryl esters are then hydrolyzed, releasing free choles 
terol and the amino acids and peptides from the de 
graded lipoprotein are excreted from the cell. The 
apolipoprotein are excreted from the cell. The apolipo 
protein B spectrum and amino acids give the peaks 
shown in FIG. 6. 
An alternative embodiment 40 of the present inven 
tion is shown in FIG. 2. In this embodiment 40, the 
probe 42 includes a substantially cylindrical shaped 
housing 44. The housing 44 is formed with a closed 
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distal end 46 from any appropriate material including 
glass and, more preferably, zirconium ?uoride glass. 
A ?ber optic bundle 48 is rigidly mounted and held in 
an end cap 50 that seals the proximal end of the housing 
44. Preferably, the end cap 50 is also made of glass that 
is, for example, heat welded to the sidewall of the cylin 
drical housing 44. 
As best shown in FIG. 3, the ?ber optic bundle 48 
includes seven individual ?ber optic strands. A cen 
trally disposed ?ber optic strand 52 (transmitting ?ber 
optic strand) is operatively connected to a light source 
54 (see also FIG. 2). This is the same type of light source 
54 described above with respect to the embodiment 
shown in FIG. 1. Six remaining ?ber optic strands 56a-f 
(receiving ?ber optic strands) are concentrically dis 
posed about the central strand 52. Each of the receiving 
strands 56a-f is operatively connected to an individual 
light detector 58a-f Once again, any type of detector 
58a-f known in the art to be suitable for the purpose 
may be utilized (e.g. lead sul?de detectors and liquid 
nitrogen cooled indium antimonide detectors). 
An inverted, substantially conical re?ector 60 is 
mounted in the housing 44 adjacent the distal end 46. 
The re?ector 60 includes a parabolically curved side 
wall speci?cally adapted for re?ecting incident light 
(note full line action arrows C) outwardly through the 
sidewall of the optically pure catheterization housing 44 
and focusing that light onto the surface of the arterial 
endothelium undergoing in vivo analysis. Scattered 
light re?ected from the arterial endothelium is directed 
by the substantially ellipsoidal sidewall of the re?ector 
60 back into the receiving ?ber optic strands 56a—f (note 
dashed line action arrows D). 
This light directing is furthered by having the distal 
end of the transmitting ?ber optic strand 52 extend a 
short distance (between 0.1 and 50.0 mm) beyond the 
distal ends of the receiving ?ber optic strands 56a- as 
shown in FIG. 2. More speci?cally light is reflected 
downwardly from the outer sidewall of the transmitting 
?ber optic strand 52 into the receiving ?ber optic 
strands 56a-f Further, each of the receiving ?ber optic 
strands 56a-f is effectively shaded from light re?ected 
by the arterial endothelium at the opposite side of the 
artery. Hence, the resulting images are clearer than 
would otherwise be obtainable. The ?ber optic strands 
56a-f direct the re?ected light to the cooperating detec 
tors 56a-f to which the ?ber optic strands are respec 
tively operatively connected. 
As indicated above with respect to the description of 
the embodiment shown in FIG. 1, the detectors 58a-f 
are operatively connected to a supercomputer 62 that 
provides analysis of the spectra detected by the detec 
tors and produces color images of the arterial endothe 
lium. These images may be utilized to determine the 
chemical composition of the arterial endothelium and 
thus, the chemical makeup of any atherosclerotic le 
sions and plaques thereon. Advantageously, by deter 
mining the chemical makeup of the lesions and plaques, 
a more effective treatment regimen may be identi?ed 
and initiated. As a result, the utilization of ineffective 
treatment regimens for the treatment of particular types 
of lesions is avoided. Hence, no time is wasted in treat 
ment and more effective and ef?cient treatment is pro 
vided for the improved safety and health of the patient 
at a lower cost. 
In accordance with the method of the present inven 
tion, in vitro analysis as described with respect to the 
embodiment shown in FIG. 1 may be simply and easily 
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completed. This is done as described above in Example 
1 by excising and partially denuding a tissue sample 
from the endothelium of a portion of a artery or vessel 
wall. The excised tissue is incubated and washed. The 
tissue is then mounted on a micropositioning stage so 
that it may be carefully analyzed by passing beneath the 
optical aperture 23 of the CPC 18. 
As discussed above, the CPC 18 focuses simulta 
neously and in parallel a limited light spectrum having 
a wavelength from 1000 to 2500 nm onto a small spot on 
the tissue sample T. More preferably, the light spectrum 
may have a wavelength range from 1500 to 2100 nm. 
This is because major spectral changes indicating the 
presence of low-density lipoprotein (LDL) may be ob 
served in this range. In order to determine the presence 
of these low-density lipoproteins with analytical preci 
sion it is necessary to utilize light across the full spec 
trum indicated. This is required as all tissue absorbs 
light at all wavelengths across this range and different 
tissues absorb only a little more at some wavelengths 
than others. As the particular wavelength(s) where 
these differences occur are not known in advance, it is 
necessary to analyze the entire range with each wave 
length being given equal weight in the analysis. Further, 
this must be done simultaneously and in parallel to in 
sure a speed of imaging necessary to make this method 
acceptable for clinical applications. Only in this way is 
it possible to avoid missing the presence of unusual 
tissue of interest to the clinician completing the study. 
Of course, as indicated above the re?ected light is ana 
lyzed using a supercomputer operatively controlled by 
appropriate software. 
In accordance with a further aspect of the present 
invention is a method of analyzing arterial endothelium 
in vivo utilizing the apparatus shown, for example, in 
FIG. 2. In accordance with this method the probe 42 is 
?rst introduced into an artery. This may be done by any 
known procedure appropriate for this purpose involv 
ing incision and opening of a portion of the artery for 
placement of the catheter probe 42 therein. Procedures 
similar to those used for the completion of angioplasty 
operations may be used for this purpose. 
After introducing the probe 42 into the artery, the 
probe is manipulated until it is positioned to allow anal 
ysis of the desired portions of the arterial endothelium. 
Once again, this positioning may be completed in accor 
dance with standard techniques utilized in angioplasty 
procedures. 
Once the probe 42 has been properly positioned, the 
method continues with the step of continuously focus 
ing simultaneously and in parallel the near infrared light 
spectrum of from 1000 to 2500 nm or more preferably 
from 1500 to 2100 nm onto the entire area of arterial 
endothelium to be analyzed. Next is the detecting of the 
light re?ected by the arterial endothelium by the detec 
tors 5811-1‘. Finally, the method concludes with the step 
of analyzing the spectra detected from the arterial endo 
thelium and producing color images thereof. 
More speci?cally, the full spectrum range of light 
originally focused upon the arterial endothelium is de 
tected simultaneously and in parallel and then analyzed 
simultaneously and in parallel. During the analysis, 
equal weighting is given to each wavelength so as to 
insure that any variations in absorbance at any wave 
length for each location of tissue undergoing analysis is 
observed. 
The present method and apparatus thereby provide 
spatially resolved chemical analysis resulting in the 
5,441,053 
production of color images that allow the doctor or lab 
technician to determine the location and quantities of 
substances such as high density lipoprotein (HDL), low 
density lipoprotein (LDL), and apolipoproteins,, such 
as apoA-I, apoA-II and apoB, in living arterial tissue. 
The result is the only known method for high speed 
parallel data acquisition and analysis of arterial lesions 
in vivo. Accurate analysis of lesions in vivo is a very 
important advance in the art as some types of lesions are 
treatable with drugs while others must be removed 
surgically. This method allows the lesions to be identi 
?ed by type. Accordingly, unnecessary surgery for 
lesion removal is now avoidable. Further, time lost 
while undergoing ineffective drug treatments may now 
be signi?cantly reduced. 
FIGS. 8a-c show near infrared spectra of human 
apolipoproteins apoA'I, apoA-II and apoB respec 
tively. As should be appreciated, the distinctive spectra 
allow the lipoprotein substances to be identi?ed. For 
example, apoA-II in HDL has a large, sharp peak near 
2050 nm that is not present in the spectra for apoA-I and 
apoB. In contrast, apoB the main apolipoprotein in 
LDL has a distinctive, sharp double peak pattern at 
approximately 1720 and 1750 nm. 
Advantageously, the ability to perform such analysis 
opens up a large number of possibilities including the 
ability to perform kinetic experiments in which the 
quantities of these lipoprotein and apolipoprotein sub 
stances are studied over time in a lesion. This may be 
done both as the lesion grows and/or as various choles 
terol-lowering drugs are administered in attempts to 
shrink the lesion. 
In summary, numerous bene?ts have been described 
which result from employing the concepts of the pres 
ent invention. The apparatus of the present invention 
including either of the embodiments shown in FIGS. 1 
or 2 may be utilized to effectively and efficiently deter 
mine the chemical composition of tissue. The proce 
dures may be completed either in vitro or in vivo and 
are particularly adapted for determining the chemical 
composition and makeup of atherosclerotic lesions as 
found on the inner walls of arterial endothelium. 
The foregoing description of a preferred embodiment 
of the invention has been presented for purposes of 
illustration and description. It is not intended to be 
exhaustive or to limit the invention to the precise form 
disclosed. Obvious modi?cations or variations are possi 
ble in light of the above teachings. The embodiment 
was chosen and described to provide. the best illustra 
tion of the principles of the invention and its practical 
application to thereby enable one of ordinary skill in the 
art to utilize the invention in various embodiments and 
with various modi?cations as is suited to the particular 
use contemplated. All such modi?cations and variations 
are within the scope of the invention as determined by 
the appended claims when interpreted in accordance 
with breadth to which they are fairly, legally and equi 
tably entitled. 
We claim: 
1. An apparatus for analyzing tissue including arterial 
lesions, comprising: 
a light generating means for transmitting simulta 
neously and in parallel an incident beam of light 
having a wavelength range from substantially 1000 
to 2500 nm; 
means for directing light from said light generating 
means onto the tissue to be analyzed; 
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?ber-optic probe means for transmitting light from 
said light generating means to said light directing 
means and for receiving light scattered by said 
tissue; 
means for detecting light simultaneously and in paral 
lel across a full wavelength range of substantially 
1000 to 2500 nm scattered by said tissue; and 
means for analyzing the detected light across a full 
wavelength range of substantially 1000 to 2500 nm. 
said ?ber opticprobe means including a centrally 
located light transmitting strand and a radial array 
of light receiving strands concentrically positioned 
around said light transmitting strand, said light 
transmitting and receiving strands each including a 
distal end and said distal end of said light transmit 
ting strand projecting beyond said distal ends of 
said light receiving strands by between 0.1 and 50.0 
mm. 
2. The apparatus set forth in claim 1, wherein light 
from said light generating means is of a more limited 
wavelength range from substantially 1500 to 2100 nm 
and said means for detecting and analyzing light func 
tions over a more limited wavelength range of substan 
tially 1500 to 2100 nm. 
3. The apparatus set forth in claim 1, wherein said 
light directing means is an inverted substantially conical 
re?ector. 
4. The apparatus set forth in claim 3, wherein said 
inverted substantially conical re?ector includes a para 
bolic sidewall for scattering incident light and focusing 
light re?ected from said tissue. 
5. A method of analyzing tissue, comprising the steps 
of: - 
focusing simultaneously and in parallel light having a 
continuous bandwidth range of at least 600 nm 
within a Wavelength range from substantially 
l,000—2,500 nm on said tissue to be analyzed; 
detecting simultaneously and in parallel light having 
said at least 600 nm bandwidth range Within a 
wavelength range from substantially l,000—2,500 
nm scattered by said tissue; and 
analyzing simultaneously and in parallel the detected 
light having said at least 600 mm bandwidth range 
within a wavelength range from substantially 
LOGO-2,500 nm while giving all wavelengths equal 
weight. 
6. The method set forth in claim 5, wherein said light 
being focused is of a more limited wavelength range 
from substantially 1500 to 2100 nm and said light detect 
ing and analyzing steps are also carried out over a more 
limited wavelength range from substantially 1500 to 
2100 nm. 
7. A method of analyzing arterial endothelium in vivo 
utilizing a ?ber optic probe, comprising the steps of: 
introducing said probe into an artery; 
focusing simultaneously and in parallel light having a 
continuous bandwidth range of at least 600 nm 
within a wavelength range from substantially 
l,000—2,500 nm on said arterial endothelium to be 
analyzed; 
detecting simultaneously and in parallel light having 
said continuous bandwidth range of at least 600 nm 
within a wavelength range from substantially 
LOGO-2,500 nm as re?ected by said arterial endo 
thelium; and 
analyzing simultaneously and in parallel the detected 
light having said continuous bandwidth range of at 
least 600 nm within a wavelength range from sub 
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stantially LOGO-2,500 nm while giving all wave 
lengths equal weight. 
8. The method set forth in claim 7, wherein said light 
being focused is of a more limited wavelength range 
from substantially 1500 to 2100 nm and said detecting 5 
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and analyzing steps are also carried out over a more 
limited wavelength range from substantially 1000 to 
2500 nm. 
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